Time New York: Fri 15 Dec 10:59 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

Zacks

On Oct 11, we issued an updated research report on New York-based DENTSPLY SIRONA Inc. XRAY — a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products.

DENTSPLY recently announced the renewal of an existing distribution agreement with Henry Schein Canada, Inc, which will continue till Dec 31, 2020. Henry Schein's agreement with DENTSPLY was initiated in August 2005.

We feel that the deal extension is a smart move by DENTSPLY as the preexisting agreement did not include the CEREC CAD/CAM restoration system and the Schick line of imaging sensors. By including the aforementioned lines of products, the company will benefit from Henry Schein’s distribution network in Canada.

Among the recent developments, DENTSPLY announced the renewal of its partnership with Pacific Dental Services. The duo’s latest agreement extends for a period of five years which was signed in 2012.
This move is also a strategic one as Pacific Dental’s network consists of over 580 centers across 17 states. During the tenure of the present agreement, management expects the number of such offices utilizing DENTSPLY technologies to exceed 800.


DENTSPLY’s dual branding strategy, product innovation, growth opportunities in emerging markets (especially Asia-Pacific and Middle East/Africa), diversified product portfolio and recurring revenue base are key catalysts. The company expects a solid guidance for full-year 2017 projecting adjusted EPS in the range of $2.65-$2.75.

On the flip side, apart from a series of macroeconomic headwinds, currency fluctuation continues to be a major dampener. In fact, strengthening of the U.S. dollar against Euro and other emerging market currencies has dented the company’s growth trajectory. Furthermore, higher capital expenditure on product development is expected to keep margins under pressure.

Share Price & Estimate Revisions Lack Luster

DENTSPLY's estimate revision trend looks unfavorable at the moment. For the third quarter, two analysts moved south, compared to no upward revision in the last two months. Notably, the current quarter estimates dropped 1.5% to 67 cents per share over the last 60 days.

DENTSPLY’s share price movement has been unfavorable over the last three months. The company shed 11.7%, much higher than the industry’s decline of 4.4%.

Zacks Rank & Key Picks

DENTSPLY currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical sector are Abbott ABT, IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO. Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 35.2% over a year.

IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 40.8% over a year.

Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock has gained 25.3% last year.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.